Activation-induced cell death in CAR-T cell therapy

Hum Cell. 2022 Mar;35(2):441-447. doi: 10.1007/s13577-022-00670-z. Epub 2022 Jan 15.

Abstract

Engineered T cells expressing chimeric antigen receptors (CARs) with tumor specificity have shown remarkable therapeutic effects on hematologic malignancies. However, CAR-T cells are less effective on solid tumors mainly due to the weak persistence of CAR-T cells, which might be caused by T cell death. Significant activation-induced cell death (AICD) of CAR-T cells was triggered by repeated antigen stimulation. AICD of T cell is characterized by the upregulation of death receptors and low persistence of T cells. Understanding the mechanism of AICD is crucial to improve the anti-tumor effect of CAR-T cells against solid tumors. Many approaches have been applied in CAR-T cell modification to enhance their anti-apoptosis ability. In this review, we summarized the molecular mechanisms of AICD in CAR-T cells and the progresses of anti-AICD in CAR-T cells therapy.

Keywords: Activation-induced cell death (AICD); CAR-T cell; Cancer immunotherapy; Solid tumor.

Publication types

  • Review

MeSH terms

  • Cell Death
  • Cell- and Tissue-Based Therapy
  • Humans
  • Immunotherapy, Adoptive
  • Neoplasms* / therapy
  • Receptors, Chimeric Antigen* / genetics
  • Receptors, Chimeric Antigen* / metabolism
  • T-Lymphocytes / metabolism

Substances

  • Receptors, Chimeric Antigen